Zobrazeno 1 - 10
of 39
pro vyhledávání: '"John P. Huberty"'
Autor:
Katherine K. Matthay, Richard Sposto, John P. Huberty, Susan Groshen, Alekist Quach, Janet Veatch, Benjamin L. Franc, Gregory A. Yanik, Denice Wei, Aimee Sznewajs, Vikash Mishra, Lingyun Ji, P. A. Fitzgerald, John M. Maris, Randall A. Hawkins, Judith G. Villablanca
Publikováno v:
Pediatric Blood & Cancer. 56:191-201
(131) I-Metaiodobenzylguanidine ((131) I-MIBG) provides targeted radiotherapy for children with neuroblastoma, a malignancy of the sympathetic nervous system. Dissociated radioactive iodide may concentrate in the thyroid, and (131) I-MIBG is concentr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bdf619793b5e496117a039769e28d5b9
https://doi.org/10.1002/pbc.22767
https://doi.org/10.1002/pbc.22767
Autor:
Suzanne Shusterman, Judith G. Villablanca, Randall A. Hawkins, Katherine K. Matthay, Susan Groshen, Benjamin L. Franc, Patricia Brophy, Gregory Yanik, Janet Veatch, John P. Huberty, Hollie A. Jackson, John M. Maris, Alekist Quach
Publikováno v:
Journal of Clinical Oncology. 27:1020-1025
Purpose Iodine-131—metaiodobenzylguanidine (131I-MIBG) provides targeted radiotherapy with more than 30% response rate in refractory neuroblastoma, but activity infused is limited by radiation safety and hematologic toxicity. The goal was to determ
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e7df7009024e93c145835719d7283035
https://doi.org/10.1200/jco.2007.15.7628
https://doi.org/10.1200/jco.2007.15.7628
Autor:
Bill Frame, Denise Regan, Katherine K. Matthay, Kenneth F. Koral, Daniel P. Normolle, Gregory A. Yanik, John M. Maris, John P. Huberty
Publikováno v:
European Journal of Nuclear Medicine and Molecular Imaging. 35:2105-2112
To compare the prediction of therapeutic hepatic radiation-absorbed dose rates from tracer imaging plus a linearity assumption to estimation based on intra-therapy imaging in (131)I metaiodobenzylguanidine (MIBG) therapy of refractory neuroblastoma.C
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c1d492cf19e362698f4ffc19e19f0606
https://doi.org/10.1007/s00259-008-0873-3
https://doi.org/10.1007/s00259-008-0873-3
Autor:
Julia A. Messina, Janet Veatch, Su-Chun Cheng, Patricia Brophy, Leslie S. Kersun, John M. Maris, John P. Huberty, Randall A. Hawkins, Robert E. Goldsby, Alekist Quach, Katherine K. Matthay, Gregory A. Yanik
Publikováno v:
Journal of Clinical Oncology. 25:1054-1060
Purpose To evaluate the effect of disease sites and prior therapy on response and toxicity after iodine-131-metaiodobenzylguanidine (131I-MIBG) treatment of patients with resistant neuroblastoma. Patients and Methods One hundred sixty-four patients w
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8ab245738b3174e8fa80652a8949b98e
https://doi.org/10.1200/jco.2006.09.3484
https://doi.org/10.1200/jco.2006.09.3484
Autor:
Katherine K. Matthay, John M. Maris, Leslie S. Kersun, Su-Chun Cheng, John P. Huberty, Randall A. Hawkins, James P. Howard
Publikováno v:
Pediatric Blood & Cancer. 44:232-239
Background 131I Metaiodobenzylguanidine (131I-MIBG) is an effective targeted radiotherapeutic for neuroblastoma with response rates greater than 30% in refractory disease. Toxicity is mainly limited to myelosuppression. The aim of this study was to d
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f4fe26a5690dea33c714d0ec72df2b49
https://doi.org/10.1002/pbc.20240
https://doi.org/10.1002/pbc.20240
Autor:
John P. Huberty, David Price, Brian Rose, Katherine K. Matthay, Barbara Klencke, Jeffrey A. Norton, Paul A. Fitzgerald
Publikováno v:
Cancer. 98:239-248
BACKGROUND 131I-Metaiodobenzylguanidine (131I-MIBG) can be used systemically to treat malignant pheochromocytoma. To improve outcome, the authors used higher levels of activity of 131I-MIBG than previously reported. The authors reported the response
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6b87013161a417099cd00455122504a8
https://doi.org/10.1002/cncr.11518
https://doi.org/10.1002/cncr.11518
Autor:
A.J. Da Silva, J.K. Brown, H.R. Tang, Randy Hawkins, Bruce H. Hasegawa, John P. Huberty, Katherine K. Matthay, David C. Price
Publikováno v:
IEEE Transactions on Nuclear Science. 46:551-557
We have developed and demonstrated an imaging system that couples an X-ray CT scanner to a scintillation camera for the localization and absolute measurement of radionuclide uptake. We use the registered CT images to provide physical information to o
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::6e99bbbab017ef63f237e790c51f81d1
https://doi.org/10.1109/23.775578
https://doi.org/10.1109/23.775578
Autor:
Robert C. Seeger, Bruce H. Hasegawa, Steven S. Goldberg, C. Patrick Reynolds, Katherine K. Matthay, Kenneth B. DeSantes, Robert S. Hattner, John P. Huberty, David H. Price
Publikováno v:
Medical and Pediatric Oncology. 30:339-346
Background Metaiodobenzylguanidine (MIBG) labeled with 131I has been used for targeted radiotherapy of neural crest tumors, with bone marrow suppression being the primary dose-limiting toxicity. The purpose of this study was to examine the engraftmen
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ceeefdff9e9a2a9b4dcb20de73612686
https://doi.org/10.1002/(sici)1096-911x(199806)30:6<339::aid-mpo7>3.0.co
https://doi.org/10.1002/(sici)1096-911x(199806)30:6<339::aid-mpo7>3.0.co
Autor:
Aimee Sznewajs, P. A. Fitzgerald, Katherine K. Matthay, Steve Shiboski, Robert E. Goldsby, Sara Gonias, David H. Price, Randall A. Hawkins, Charles A. Linker, Lloyd E. Damon, John P. Huberty
Publikováno v:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 27(25)
Purpose To evaluate the safety and efficacy of high-dose [131I]metaiodobenzylguanidine ([131I]MIBG) in the treatment of malignant pheochromocytoma (PHEO) and paraganglioma (PGL). Methods Fifty patients with metastatic PHEO or PGL, age 10 to 64 years,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::46df37be862c721fe5e1eff60ddae531
https://pubmed.ncbi.nlm.nih.gov/19636009
https://pubmed.ncbi.nlm.nih.gov/19636009
Autor:
Randall A. Hawkins, Filemon Dela Cruz, David C. Price, Janet Veatch, Lloyd E. Damon, John P. Huberty, Charles A. Linker, Thierry Jahan, Katherine K. Matthay, Robert E. Goldsby, P. A. Fitzgerald
Publikováno v:
Annals of the New York Academy of Sciences. 1073
Thirty patients with malignant pheochromocytoma (PHEO) or paraganglioma (PGL) were treated with high-dose 131I-MIBG. Patients were 11-62 (mean 39) years old: 19 patients males and 11 females. Nineteen patients had PGL, three of which were multifocal.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::071d5ee59be3de3debadbaa47d1dea9e
https://pubmed.ncbi.nlm.nih.gov/17102115
https://pubmed.ncbi.nlm.nih.gov/17102115